Evidence map›Paper›PMID 40500141›Full record

ArticleBMJ (Clinical research ed.)2025

Oral contraceptives with progestogens desogestrel or levonorgestrel and risk of intracranial meningioma: national case-control study.

Noémie Roland, Epiphane Kolla, Bérangère Baricault, Pauline Dayani, Lise Duranteau, Sébastien Froelich, Mahmoud Zureik, Alain Weill

Abstract read
In one paragraph

Article in BMJ (Clinical research ed.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Noémie RolandEPI-PHARE Scientific Interest Group, French National Agency for Medicines and Health Products Safety, French National Health Insurance, 93285 Saint-Denis, France.ORCID 0000-0002-8079-4263
Epiphane KollaEPI-PHARE Scientific Interest Group, French National Agency for Medicines and Health Products Safety, French National Health Insurance, 93285 Saint-Denis, France.ORCID 0000-0003-4649-6833
Bérangère BaricaultEPI-PHARE Scientific Interest Group, French National Agency for Medicines and Health Products Safety, French National Health Insurance, 93285 Saint-Denis, France.ORCID 0000-0001-5835-7668
Pauline DayaniFrench National Agency for Medicines and Health Products Safety, Saint-Denis, France.ORCID 0000-0002-8653-928X
Lise DuranteauDepartment of Medical Gynaecology, Bicêtre Hospital, Paris Saclay University, Assistance Publique-Hôpitaux de Paris, Le Kremlin-Bicêtre, France.ORCID 0000-0001-9434-248X
Sébastien FroelichDepartment of Neurosurgery, Lariboisière University Hospital, Paris-Cité University, Assistance Publique-Hôpitaux de Paris, Paris, France.ORCID 0000-0001-9124-2395
Mahmoud ZureikEPI-PHARE Scientific Interest Group, French National Agency for Medicines and Health Products Safety, French National Health Insurance, 93285 Saint-Denis, France.ORCID 0000-0002-8393-4217
Alain WeillEPI-PHARE Scientific Interest Group, French National Agency for Medicines and Health Products Safety, French National Health Insurance, 93285 Saint-Denis, France.ORCID 0000-0001-8687-9092

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo assess the risk of intracranial meningioma associated with oral contraceptives containing desogestrel, levonorgestrel, or levonorgestrel combined with oestrogen.

designCase-control study.

settingFrench national health data system (Système National des Données de Santé).

participants8391 women living in France who required surgery for intracranial meningioma in 2020-23. Each patient was matched to 10 women without intracranial meningioma (controls) on year of birth and area of residence.

main outcome measureRisk of intracranial meningioma associated with oral contraceptives containing desogestrel 75µg, levonorgestrel 30µg, or levonorgestrel 50-150 µg combined with oestrogen, and duration of use: short term use was defined by one or more dispensations within the year before the index date only, and prolonged use was defined by continuous use of one year or more (up to seven or more years of continuous use). Conditional logistic regression was used to calculate odds ratios.

results92 301 women, mean age 59.7 years (standard deviation 12.9 years), were included. Among 8391women who had undergone surgery for intracranial meningioma, 287 (3.4%) used desogestrel 75µg (

conclusionsThe results showed a small increased risk of intracranial meningioma in women who had used desogestrel 75 µg for more than five continuous years, but no risk in users of levonorgestrel (alone or combined with oestrogen).

Indexed as

DesogestrelLevonorgestrelMeningeal NeoplasmsMeningiomaAdultAgedCase-Control StudiesEstrogensFemaleFranceHumansMiddle AgedProgestinsRisk FactorsDesogestrelEstrogensLevonorgestrelProgestins

Identifiers

PMID40500141
PMCPMC12153057

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.